Search for a clinical trial
Other search option(s)
11 Result(s)
Recruiting trial
= 
; Ongoing trial
= 
; Terminated trial = 
; Funded by an IRDiRC member = 
; Study involving ERN members in at least two Member States = 
National clinical trial(s)
AUSTRIA
WIEN
WIEN
ANNOUNCE: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Doxorubicin Plus Olaratumab Versus Doxorubicin Plus Placebo in Patients With Advanced or Metastatic Soft Tissue Sarcoma - AT
Universitätsklinikum - AKH Wien
Klinische Abteilung für Onkologie
BELGIUM
VLAAMS BRABANT
LEUVEN
An Open-Label, Multicenter, Phase 1a/1b Study of Olaratumab (LY3012207) Plus Pembrolizumab (MK3475) in Patients With Unresectable Locally Advanced or Metastatic Soft Tissue Sarcoma (STS) Who Have Failed Standard Treatments - BE
UZ Leuven - Campus Gasthuisberg
General medical oncology/Dienst Algemene Medische Oncologie
GERMANY
Baden-Württemberg
ULM
ANNOUNCE 2: A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Gemcitabine and Docetaxel With or Without Olaratumab in the Treatment of Advanced Soft Tissue Sarcoma -DE- Prematurely Ended
Integratives Tumorzentrum des Universitätsklinikums Ulm
Comprehensive Cancer Center (CCC) Ulm
HUNGARY
Észak-Alföld
DEBRECEN
ANNOUNCE 2: A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Gemcitabine and Docetaxel With or Without Olaratumab in the Treatment of Advanced Soft Tissue Sarcoma - HU
Debreceni Egyetem Klinikai Központ Onkológiai Intézet
Institute of Oncology
SPAIN
Comunidad Valenciana
VALENCIA
ANNOUNCE: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Doxorubicin plus Olaratumab versus Doxorubicin plus Placebo in Patients with Advanced or Metastatic Soft Tissue Sarcoma -ES
Hospital Universitario y Politécnico La Fe
Servicio de Oncología Médica
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
A Phase 2 Study of a Human Anti-PDGFR Alpha Monoclonal Antibody (IMC-3G3) in Previously Treated Patients With Unresectable and/or Metastatic Gastrointestinal Stromal Tumors (GIST) - ES (completed)
Institution: Information not provided - ES
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
ANNOUNCE 2: A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Gemcitabine and Docetaxel With or Without Olaratumab in the Treatment of Advanced Soft Tissue Sarcoma - ES (completed)
Institution: Information not provided - ES
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
A Phase 1b Trial to Assess the Modulation of Biological Markers in Patients With Potentially Resectable Soft Tissue Sarcoma Treated With Olaratumab Monotherapy Followed by Olaratumab Plus Doxorubicin Combination Therapy - ES (completed)
Institution: Information not provided - ES
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
OLATRASTS: Phase I Clinical Trial of Olaratumab Plus Trabectedin in Advanced Soft-tissue Sarcoma Patients -ES
Institution: Information not provided - ES
SWITZERLAND
Suisse Romande
ADDRESS: NOT PROVIDED - CH
ANNOUNCE 2: A Phase 1b (Open-Label) / Phase 2 (Randomized,Double-Blinded) Study Evaluating Gemcitabine andDocetaxel With or Without Olaratumab in the Treatment ofAdvanced Soft Tissue Sarcoma -GB
Institution: Information not provided - CH
UNITED STATES
Washington
ADDRESS: NOT PROVIDED - US